Plain-English translation of NCT05722405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether combining with a low dose of lenalidomide works better than alone for patients with aggressive multiple myeloma. Both are oral medications taken as maintenance therapy — meaning they help keep the disease from coming back after you've already received initial treatment (like chemotherapy and possibly a stem cell transplant). The study wants to see if the combination approach improves how long patients stay in remission and survive.
Patients with aggressive, high-risk multiple myeloma often have their cancer return even after successful initial treatment. Researchers want to find out whether adding a second medication to the maintenance regimen can help keep the disease under control longer and improve survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either alone or combined with low-dose lenalidomide as an oral maintenance regimen. You'll take these medications at home following a regular schedule while your doctors monitor your health with periodic blood tests and clinic visits. The study is designed to track how well each approach works at keeping your cancer in remission over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China